OrthoPediatrics (KIDS) Stock Price

OrthoPediatrics Price

NASDAQ·CLOSED
24.56USD+1.28 (+5.35 %)
Market closed

Over the last 11 years OrthoPediatrics grew revenue by 23.3% annually, reaching 236.35 M USD. For OrthoPediatrics, the net margin of -16.8% is broadly stable versus -16.6% a few years ago. The consensus 12-month price target for OrthoPediatrics is 23.46 USD, about 4.5% below where the stock trades today. Of 15 analysts, 13 rate the stock a buy — an overall Buy consensus. The stock trades about 68% above its 52-week low.

OrthoPediatrics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of OrthoPediatrics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how OrthoPediatrics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing OrthoPediatrics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

OrthoPediatrics Stock Price History
DateOrthoPediatrics Price
8/12/202624.56 USD
8/10/202623.28 USD
8/7/202622.77 USD
8/6/202622.83 USD
8/5/202621.58 USD
8/4/202620.83 USD
8/3/202620.87 USD
7/31/202620.19 USD
7/30/202620.11 USD
7/29/202619.90 USD
7/27/202619.46 USD
7/23/202618.72 USD
7/22/202619.26 USD
7/21/202619.49 USD
7/20/202619.52 USD
7/17/202619.22 USD
7/16/202620.38 USD
7/15/202619.72 USD
7/14/202619.25 USD
7/13/202620.80 USD
7/10/202620.33 USD
7/9/202620.23 USD
7/8/202619.37 USD
7/7/202619.82 USD
7/6/202619.77 USD
7/2/202619.95 USD
7/1/202619.30 USD
6/30/202619.13 USD
6/29/202620.08 USD
6/26/202620.30 USD
6/25/202619.62 USD
6/24/202619.14 USD
6/23/202618.38 USD
6/22/202618.51 USD
6/18/202618.37 USD
6/17/202618.38 USD
6/16/202618.55 USD
6/15/202618.10 USD
6/12/202617.99 USD
6/11/202618.11 USD
6/10/202618.79 USD
6/9/202618.49 USD
6/8/202618.23 USD
6/5/202618.32 USD
6/4/202618.10 USD
6/3/202616.92 USD
6/2/202616.81 USD
6/1/202616.65 USD
5/29/202617.17 USD
5/28/202617.81 USD
5/27/202617.55 USD
5/26/202617.90 USD
5/22/202618.37 USD
5/21/202618.43 USD
5/20/202618.50 USD
5/19/202618.23 USD
5/18/202618.14 USD
5/15/202617.72 USD
5/14/202617.90 USD
5/13/202617.79 USD
5/12/202617.72 USD
5/11/202617.18 USD
5/8/202617.81 USD
5/7/202617.57 USD
5/6/202617.12 USD
5/5/202617.04 USD
5/4/202615.78 USD
5/1/202615.63 USD
4/30/202615.06 USD
4/29/202614.64 USD
4/28/202615.14 USD
4/27/202615.82 USD
4/24/202616.19 USD
4/23/202616.21 USD
4/22/202616.37 USD
4/21/202616.25 USD
4/20/202616.65 USD
4/17/202616.75 USD
4/16/202616.53 USD
4/15/202617.85 USD
4/14/202617.86 USD
4/13/202616.95 USD
4/10/202615.97 USD
4/9/202615.94 USD
4/8/202616.01 USD
4/7/202615.76 USD
4/6/202615.94 USD
4/2/202616.06 USD
4/1/202616.29 USD
3/31/202615.87 USD
3/30/202615.20 USD
3/27/202615.52 USD
3/26/202616.35 USD
3/25/202616.35 USD
3/24/202616.23 USD
3/23/202615.91 USD
3/22/202616.47 USD
3/20/202616.52 USD
3/19/202616.52 USD
3/18/202616.54 USD
3/17/202616.66 USD
3/16/202617.21 USD
3/15/202617.11 USD
3/13/202617.31 USD
3/12/202617.31 USD
3/11/202617.54 USD
3/10/202617.80 USD
3/9/202617.81 USD
3/8/202618.78 USD
3/6/202618.05 USD
3/5/202618.05 USD
3/4/202617.82 USD
3/3/202618.48 USD
3/2/202618.67 USD
3/1/202619.22 USD
2/27/202619.17 USD
2/26/202619.17 USD
2/25/202617.79 USD
2/24/202616.72 USD
2/23/202616.08 USD
2/22/202616.30 USD
2/20/202616.96 USD
2/19/202616.96 USD
2/18/202617.05 USD
2/17/202617.09 USD
2/16/202617.05 USD
2/13/202616.89 USD
2/12/202616.89 USD
2/11/202616.72 USD
2/10/202617.22 USD
2/9/202617.08 USD
2/8/202616.71 USD
2/6/202616.65 USD
2/5/202616.65 USD
2/4/202616.59 USD
2/3/202616.90 USD
2/2/202616.97 USD
2/1/202617.29 USD
1/30/202617.46 USD
1/29/202617.46 USD
1/28/202617.29 USD
1/27/202617.32 USD
1/26/202617.74 USD
1/25/202617.78 USD
1/23/202618.11 USD
1/22/202618.11 USD
1/21/202618.49 USD
1/20/202618.64 USD
1/19/202618.45 USD
1/16/202618.35 USD
1/15/202618.35 USD
1/14/202618.71 USD
1/13/202618.44 USD
1/12/202618.69 USD
1/11/202620.11 USD
1/9/202618.31 USD
1/8/202618.31 USD
1/7/202618.73 USD
1/6/202618.39 USD
1/5/202618.74 USD
1/4/202618.17 USD
1/2/202617.56 USD
1/1/202617.56 USD
12/31/202517.76 USD
12/30/202517.76 USD
12/29/202517.96 USD
12/28/202517.63 USD
12/26/202517.34 USD
12/25/202517.34 USD
12/24/202517.41 USD
12/23/202517.41 USD
12/22/202517.28 USD
12/21/202517.36 USD
12/19/202517.07 USD
12/18/202517.07 USD
12/17/202517.57 USD
12/16/202517.32 USD
12/15/202517.91 USD
12/14/202517.99 USD
12/12/202517.60 USD
12/11/202517.60 USD
12/10/202518.33 USD
12/9/202518.79 USD
12/8/202518.34 USD
12/7/202518.23 USD
12/5/202518.41 USD
12/4/202518.41 USD
12/3/202518.17 USD
12/2/202517.93 USD
12/1/202517.70 USD
11/30/202517.94 USD
11/28/202518.49 USD
11/27/202518.49 USD
11/26/202518.59 USD
11/25/202518.59 USD
11/24/202519.09 USD
11/23/202518.07 USD
11/21/202517.85 USD
11/20/202517.85 USD
11/19/202516.87 USD
11/18/202516.62 USD
11/17/202516.35 USD
11/16/202516.32 USD
11/14/202516.71 USD
11/13/202516.71 USD
11/12/202516.92 USD
11/11/202516.99 USD
11/10/202517.21 USD
11/9/202516.83 USD
11/7/202517.01 USD
11/6/202517.01 USD
11/5/202516.40 USD
11/4/202516.37 USD
11/3/202516.58 USD
11/2/202516.41 USD
10/31/202516.84 USD
10/30/202516.84 USD
10/29/202516.47 USD
10/28/202516.46 USD
10/27/202516.91 USD
10/26/202516.96 USD
10/23/202517.03 USD
10/22/202517.06 USD
10/21/202517.88 USD
10/20/202517.91 USD
10/19/202517.61 USD
10/16/202517.24 USD
10/15/202517.80 USD
10/14/202517.85 USD
10/13/202517.68 USD
10/12/202517.51 USD
10/9/202516.30 USD
10/8/202517.95 USD
10/7/202518.10 USD
10/6/202518.09 USD
10/5/202518.24 USD
10/2/202518.77 USD
10/1/202517.93 USD
9/30/202518.42 USD
9/29/202518.53 USD
9/28/202518.31 USD
9/25/202518.28 USD
9/24/202518.02 USD
9/23/202518.89 USD
9/22/202518.94 USD
9/21/202519.35 USD
9/18/202519.18 USD
9/17/202520.11 USD
9/16/202519.25 USD
9/15/202519.59 USD
9/14/202519.56 USD
9/11/202519.65 USD
9/10/202520.33 USD
9/9/202519.29 USD
9/8/202520.49 USD
9/7/202520.91 USD
9/4/202520.91 USD
9/3/202520.71 USD
9/2/202520.90 USD
9/1/202520.80 USD
8/28/202521.36 USD
8/27/202521.44 USD
8/26/202521.63 USD
8/25/202522.12 USD
8/24/202520.29 USD
8/21/202520.20 USD
8/20/202519.15 USD
8/19/202519.48 USD
8/18/202519.13 USD
8/17/202519.20 USD
Access this data via the Eulerpool API
Get Free API Key

OrthoPediatrics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
148.73 M USD
-26.75 M USD
-20.97 M USD
Jan 1, 2024
204.73 M USD
-39.31 M USD
-37.82 M USD
Jan 1, 2025
236.35 M USD
-33.19 M USD
-39.65 M USD
Jan 1, 2026 (e)
265.24 M USD
-28.25 M USD
-29.59 M USD
Jan 1, 2027 (e)
296.69 M USD
-31.59 M USD
-20.26 M USD
Jan 1, 2028 (e)
330.47 M USD
-35.19 M USD
-7.21 M USD
Jan 1, 2029 (e)
370.90 M USD
-39.50 M USD
4.77 M USD
Jan 1, 2030 (e)
413.10 M USD
-43.99 M USD
22.82 M USD

OrthoPediatrics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 15, 2026, 4:25 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
31.0037.0045.0057.0072.0071.0098.00122.00148.00204.00236.00265.00296.00330.00370.00413.00
34.7819.3521.6226.6726.32-1.3938.0324.4921.3137.8415.6912.2911.7011.4912.1211.62
67.7470.2775.5673.6875.0077.4674.4973.7775.0072.5572.8872.8872.8872.8872.8872.88
21.0026.0034.0042.0054.0055.0073.0090.00111.00148.00172.00193.14215.73240.51269.66301.00
-6.00-5.00-6.00-9.00-9.00-30.00-18.00-21.00-26.00-39.00-33.00-28.00-31.00-35.00-39.00-43.00
-19.35-13.51-13.33-15.79-12.50-42.25-18.37-17.21-17.57-19.12-13.98-10.57-10.47-10.61-10.54-10.41
-7.00-6.00-8.00-12.00-13.00-32.00-16.001.00-20.00-37.00-39.00-29.00-20.00-7.004.0022.00
-22.22-14.2933.3350.008.33146.15-50.00-106.25-2,100.0085.005.41-25.64-31.03-65.00-157.14450.00
7.517.514.8313.0115.0319.1219.3022.4722.7623.1723.5823.5823.5823.5823.5823.58
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales OrthoPediatrics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue OrthoPediatrics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare OrthoPediatrics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares OrthoPediatrics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against OrthoPediatrics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

OrthoPediatrics stock margins

The OrthoPediatrics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of OrthoPediatrics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for OrthoPediatrics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
74.86 %
-18.38 %
-16.58 %
Jan 1, 2022
74.14 %
-17.82 %
1.03 %
Jan 1, 2023
74.80 %
-17.99 %
-14.10 %
Jan 1, 2024
72.58 %
-19.20 %
-18.47 %
Jan 1, 2025
73.05 %
-14.04 %
-16.78 %
Jan 1, 2026 (e)
73.05 %
-10.65 %
-11.16 %
Jan 1, 2027 (e)
73.05 %
-10.65 %
-6.83 %
Jan 1, 2028 (e)
73.05 %
-10.65 %
-2.18 %

OrthoPediatrics Stock Revenue, EBIT, Earnings per Share

The OrthoPediatrics earnings per share therefore indicates how much revenue OrthoPediatrics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
5.08 USD
-0.93 USD
-0.84 USD
Jan 1, 2022
5.44 USD
-0.97 USD
0.06 USD
Jan 1, 2023
6.53 USD
-1.18 USD
-0.92 USD
Jan 1, 2024
8.84 USD
-1.70 USD
-1.63 USD
Jan 1, 2025
10.02 USD
-1.41 USD
-1.68 USD
Jan 1, 2026 (e)
10.58 USD
-1.20 USD
-1.18 USD
Jan 1, 2027 (e)
11.83 USD
-1.34 USD
-0.81 USD
Jan 1, 2028 (e)
13.18 USD
-1.49 USD
-0.29 USD

OrthoPediatrics business model & stock analysis

OrthoPediatrics Corp is an American company specializing in products and solutions for orthopedic disorders in children and adolescents. The company was founded in 2006 and is headquartered in Warsaw, Indiana. Business model: The business model of OrthoPediatrics Corp focuses on the development and marketing of implants and surgical instruments for the treatment of orthopedic disorders in children and adolescents. The company works closely with specialists and hospitals to develop innovative and specialized products that meet the needs of children and adolescents. The company specializes in three areas: 1. Trauma and deformity correction – treatment of spinal and limb injuries as well as congenital deformity disorders in children and adolescents. 2. Scoliosis and spinal surgery – correction of spinal deformity and treatment of scoliosis and kyphosis in children and adolescents. 3. Sports medicine and orthobiology – development of solutions to support bone healing and regeneration in children and adolescents after an injury or surgery. Products: OrthoPediatrics Corp offers a variety of products tailored to the specific needs and requirements of children and adolescents. These include: - Bands and implants for repairing broken bones and joint injuries. - Surgical instruments and implants for correcting spinal and limb deformities such as scoliosis. - Technologies to promote bone healing and regeneration, such as BioCartilage and Pedigree matrix. OrthoPediatrics Corp also has partnerships with other companies, such as Bioretec and PhyzioMedics, to develop innovative products and solutions that meet the needs of children and adolescents. Conclusion: OrthoPediatrics Corp is a leading provider of orthopedic solutions for children and adolescents. The company has a long history and an excellent reputation for developing innovative products and solutions tailored to the specific needs and requirements of this age group. The company works closely with specialists and hospitals to ensure that its products meet the highest medical standards and effectively help patients.

OrthoPediatrics SWOT Analysis

Strengths

OrthoPediatrics Corp is known for its continuous product innovation in the field of pediatric orthopedics. This strength allows the company to stay competitive and cater to the unique needs of pediatric patients.

With a focus solely on pediatric orthopedics, OrthoPediatrics Corp has established itself as a leader in this niche market. This specialization enables the company to provide highly specialized and targeted solutions to its customers.

Weaknesses

OrthoPediatrics Corp relies heavily on a few key customers for a significant portion of its revenue. This dependence poses a risk, as any loss of these customers could have a substantial negative impact on the company's financial performance.

Despite its success in the domestic market, OrthoPediatrics Corp has a relatively limited global presence compared to some of its competitors. This limited reach may restrict the company's growth opportunities in international markets.

Opportunities

There is a growing demand for pediatric orthopedic solutions due to an increasing focus on children's health and well-being. OrthoPediatrics Corp can take advantage of this opportunity by further expanding its product offerings and targeting new customer segments.

OrthoPediatrics Corp can explore expansion opportunities in emerging markets, where there is a rising need for specialized orthopedic solutions for children. By entering these markets early, the company can gain a competitive advantage and establish a strong presence.

Threats

The pediatric orthopedic industry is highly competitive, with numerous players competing for market share. OrthoPediatrics Corp faces the threat of intense competition, which could potentially impact its market position and profitability.

The healthcare industry is subject to various regulations and compliance requirements. OrthoPediatrics Corp may face challenges in navigating these regulations, which could result in increased costs and delays in product approvals.

OrthoPediatrics Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

OrthoPediatrics Employees
Details
Date
OrthoPediatrics Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

OrthoPediatrics Segments

OrthoPediatrics Revenue by Segment (1/4)

  • 3 Years

  • Max

Trauma and deformity
Scoliosis
Sports medicine/other
Details
Date
Trauma and deformity
Scoliosis
Sports medicine/other
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
85.06 M USD
33.43 M USD
3.81 M USD
Jan 1, 2023
106.78 M USD
37.93 M USD
4.02 M USD
Jan 1, 2024
145.13 M USD
55.15 M USD
4.45 M USD
Jan 1, 2025
166.30 M USD
66.05 M USD
4.00 M USD

OrthoPediatrics Revenue by Segment (2/4)

  • 3 Years

  • Max

Trauma and deformity
Scoliosis
Sports medicine/other
Details
Date
Trauma and deformity
Scoliosis
Sports medicine/other
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
65.83 M USD
28.05 M USD
4.17 M USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD

OrthoPediatrics Revenue by Segment (3/4)

  • 3 Years

  • 5 Years

  • Max

Trauma and deformity
Scoliosis
Sports medicine/other
Details
Date
Trauma and deformity
Scoliosis
Sports medicine/other
Jan 1, 2018
39.70 M USD
16.66 M USD
1.20 M USD
Jan 1, 2019
49.37 M USD
21.49 M USD
1.70 M USD
Jan 1, 2020
47.68 M USD
20.74 M USD
2.66 M USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD

OrthoPediatrics Revenue by Segment (4/4)

  • 3 Years

  • 5 Years

  • Max

Trauma and deformity
Scoliosis
Sports medicine/other
Details
Date
Trauma and deformity
Scoliosis
Sports medicine/other
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2020
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD

OrthoPediatrics Revenue by Region

  • 3 Years

  • 5 Years

  • Max

United States
International
Details
Date
United States
International
Jan 1, 2017
34.91 M USD
10.71 M USD
Jan 1, 2022
92.42 M USD
29.87 M USD
Jan 1, 2023
111.01 M USD
37.72 M USD
Jan 1, 2024
161.16 M USD
43.56 M USD
Jan 1, 2025
186.40 M USD
49.95 M USD

OrthoPediatrics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

OrthoPediatrics historical P/E ratio, EBIT multiple, and P/S ratio

OrthoPediatrics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

OrthoPediatrics shares outstanding

The number of shares of OrthoPediatrics was 23.58 M in 2025. This indicates how many shares OrthoPediatrics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
19.30 M Stocks
Jan 1, 2022
22.47 M Stocks
Jan 1, 2023
22.76 M Stocks
Jan 1, 2024
23.17 M Stocks
Jan 1, 2025
23.58 M Stocks
Jan 1, 2026 (e)
23.58 M Stocks
Jan 1, 2027 (e)
23.58 M Stocks
Jan 1, 2028 (e)
23.58 M Stocks

Current OrthoPediatrics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
2.13 %
Buy
86.67 % (13)
Hold
13.33 % (2)
Sell
0.00 % (0)
12M Price Target
23.46
Last Price
25.01
Currency
USD
12M Return Potential
-6.20 %
LTM Return
0 %

OrthoPediatrics Analyst Rating Actions

DateFirmActionRatingReliability
7/16/2026
Truist Securities
Truist Securities
MaintainedHold–
5/1/2026
BTIG
BTIG
MaintainedBuy–
3/2/2026
Truist Securities
Truist Securities
MaintainedHold–
2/27/2026
Needham
Needham
MaintainedBuy70
2/27/2026
BTIG
BTIG
MaintainedBuy–
10/29/2025
Needham
Needham
MaintainedBuy70
10/29/2025
BTIG
BTIG
MaintainedBuy–
10/10/2025
Stifel
Stifel
MaintainedBuy–
10/10/2025
Piper Sandler
Piper Sandler
MaintainedOverweight51
10/10/2025
Lake Street
Lake Street
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

OrthoPediatrics Earnings Calls

2025

OrthoPediatrics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/3/2026-0.31USD-69.61 MUSD-2026 Q2
5/5/2026-0.49USD-59.48 MUSD-2026 Q1
3/2/2026-0.34USD-61.15 MUSD-2025 Q4
4/29/2024-0.34USD-38.40 MUSD-2024 Q1
2/26/2024-0.28USD-38.49 MUSD-2023 Q4
8/1/2023-0.16USD-40.23 MUSD-2023 Q2
5/2/2023-0.34USD-31.14 MUSD-2023 Q1
2/28/2023-0.26USD-33.68 MUSD-2022 Q4
10/31/2022-0.21USD-36.93 MUSD-2022 Q3
8/3/2022-0.22USD-32.88 MUSD-2022 Q2

EESG©

Eulerpool ESG Scorecard© for the OrthoPediatrics stock

29/100
33
Environment
51
Social
3
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions179
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

OrthoPediatrics shareholder structure

% Name
6.47807%
Brown Advisory
Brown Advisory
6.20695%
Brown Capital Management, LLC
Brown Capital Management, LLC
4.41918%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
4.41695%
Braidwell LP
Braidwell LP
4.09388%
Wellington Management Company, LLP
Wellington Management Company, LLP
3.85498%
Granahan Investment Management, LLC
Granahan Investment Management, LLC
...

OrthoPediatrics Beneficial Ownership Filings (SEC 13D/G)

Free Float
66.5%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
27.50%
David R. Pelizzon
David R. Pelizzon
SEC ↗
27.40%
Squadron Capital LLC
Squadron Capital LLC
SEC ↗
27.40%
Jennifer N. Pritzker
Jennifer N. Pritzker
SEC ↗
5.62%
41-1930193
41-1930193
SEC ↗
5.57%
Brown Advisory Incorporated ("BAI")
Brown Advisory Incorporated ("BAI")
SEC ↗
5.54%
Brown Advisory LLC ("BALLC")
Brown Advisory LLC ("BALLC")
SEC ↗
5.30%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
5.12%
5.12% (1)
5.12% (1)
SEC ↗
4.96%
BlackRock, Inc.
BlackRock, Inc.
SEC ↗
4.31%
Brown Capital Management, LLC
Brown Capital Management, LLC
SEC ↗

OrthoPediatrics Executives and Management Board

15 members · avg. age 60 · 13 % women

DB

Mr. David Bailey (46)

President, Chief Executive Officer, Director · since 2009

3.66 M USD

Management

FH

Mr. Fred Hite (57)

Chief Financial Officer, Chief Operating Officer, Director · since 2015

2.58 M USD
JH

Mr. Joseph Hauser (43)

President of Trauma, Deformity and OPSB

1.74 M USD
GO

Mr. Gregory Odle (55)

President of Scoliosis

1.60 M USD
DG

Mr. Daniel Gerritzen (55)

Executive Vice President - Legal, General Counsel, Company Secretary

1.60 M USD
PT

Mr. Philip Taylor

Investor Relations · since 2022

–

Board of Directors

BH

Mr. Bryan Hughes (47)

Independent Director

190,000.00 USD
MI

Ms. Marie Infante (75)

Independent Director

185,000.00 USD
GD

Dr. George Dyer (57)

Independent Director

180,000.00 USD
JM

Mr. Jimmy Mcdonald (64)

Independent Director

180,000.00 USD
DP

Mr. David Pelizzon (69)

Independent Director

180,000.00 USD
SR

Mr. Samuel Riccitelli (66)

Independent Director

180,000.00 USD

OrthoPediatrics Supply Chain

Frequently asked questions about OrthoPediatrics

The business model of OrthoPediatrics Corp revolves around designing, developing, and selling of orthopedic implants and instruments specifically for children. OrthoPediatrics focuses on serving the needs of healthcare professionals who specialize in pediatric orthopedics by offering a comprehensive product portfolio. They aim to improve the quality of life for children with orthopedic conditions, providing innovative solutions tailored to their unique and growing anatomies. OrthoPediatrics' business model is centered on delivering specialized pediatric orthopedic implants, surgical instruments, and related services, thereby catering to the specific requirements of pediatric patients and addressing a niche market in the medical industry.

OrthoPediatrics Corp is primarily active in the medical device industry, specifically focusing on orthopedic products and solutions for children.

Some of the main competitors of OrthoPediatrics Corp in the market include Zimmer Biomet Holdings Inc., Johnson & Johnson, and Stryker Corporation.

OrthoPediatrics Corp is a leading orthopedic company specializing in pediatric orthopedic medical devices and technologies. Founded in 2006, the company has established itself as a prominent player in the market, catering exclusively to the unique needs of children. OrthoPediatrics Corp focuses on developing innovative solutions that address a wide range of orthopedic conditions in pediatric patients. With an extensive product portfolio and a strong commitment to research and development, the company has continuously expanded its presence globally. OrthoPediatrics Corp's dedication to improving the lives of children through orthopedic advancements has earned it a reputable standing in the industry.

OrthoPediatrics Corp has achieved several significant milestones. Since its inception, the company has demonstrated strong growth and innovation. It became the first company to develop a comprehensive pediatric-specific surgical implant offering. OrthoPediatrics Corp has successfully introduced advanced implants and instruments specifically designed for pediatric orthopedic surgery, addressing unmet medical needs. The company has also expanded globally, establishing a presence in over 50 countries, which has further contributed to its success. OrthoPediatrics Corp continues to pioneer in pediatric orthopedics, providing specialized solutions that improve the quality of care for children with musculoskeletal conditions.

OrthoPediatrics Corp is primarily present in the United States.

OrthoPediatrics Corp represents values of innovation, integrity, and commitment to improving pediatric orthopedic care. The company's corporate philosophy revolves around providing advanced solutions to address the unique needs of children, ensuring positive outcomes and improved quality of life. OrthoPediatrics Corp's focus on research and development, collaborative partnerships, and the highest standards of patient care showcases their strong commitment to advancing pediatric orthopedics. By leveraging cutting-edge technology and expertise, OrthoPediatrics Corp strives to enhance surgical procedures, develop innovative implants and instruments, and ultimately make a significant difference in the lives of pediatric patients worldwide.

Analysts currently set an average price target of 24.48 USD for the OrthoPediatrics stock (median: 23.46 USD), implying -2.1 % versus the latest price. The consensus is based on 15 analyst ratings.

OrthoPediatrics Analyst Price Targets 2026

15 analysts currently rate the OrthoPediatrics stock: 13 recommend buying, 2 holding and 0 selling. For 2026, analysts expect OrthoPediatrics to generate revenue of 265.24 M USD and earnings per share of -1.26 USD.

OrthoPediatrics Analyst Price Targets 2026

Converted at the current exchange rate, the OrthoPediatrics share trades at 21.23 EUR (24.56 USD).

The OrthoPediatrics share (KIDS) is listed on 2 stock exchanges, including: NASDAQ (KIDS), Frankfurt (2X7.F).

OrthoPediatrics Corp is a global provider of orthopedic implants and instruments for the pediatric market. The company was founded in 2006 and is headquartered in the USA. Its goal is to support children and adolescents with orthopedic conditions and enable them to lead active lives. The company has three different business areas: Products, Operative Services, and Education Services. In the Products area, OrthoPediatrics Corp offers a wide range of implants and instruments specifically designed for the treatment of children and adolescents. They offer over 30 surgical systems that can be used for a variety of diagnoses such as scoliosis, hip dysplasia, or fractures. A significant product that OrthoPediatrics Corp offers is the Pediatric Nailing System, a central technology used to manufacture many of their surgical systems. This system is specifically designed for the needs of children and adolescents and facilitates quick and accurate treatment for surgeons. Operative Services is the second business area of OrthoPediatrics Corp. Here, the company offers a variety of service options tailored to the needs of children and adolescents. This includes support for surgery planning, delivery of instruments and implants to the operating site, and providing training for medical personnel. The third business area of OrthoPediatrics Corp is education. The company offers a variety of training programs to educate doctors and medical personnel on the latest technologies and treatment methods for children and adolescents. OrthoPediatrics Corp aims to train doctors and medical personnel on handling children and adolescents through workshops, seminars, and training sessions for doctors, nurses, and other medical staff. OrthoPediatrics Corp's business model is based on the belief that there are no simple operations for children and adolescents. Therefore, the company has developed products and services that consider the specific needs of children and adolescents. The company pursues a strong brand strategy in the pediatric orthopedics market and has established a strong presence in this field. OrthoPediatrics Corp aims to further expand its market position and plans to focus strongly on international markets in the coming years. The company works closely with medical facilities, surgeons, and hospitals to provide advanced technology, excellent service, and training. OrthoPediatrics Corp will continue to be a strong partner for healthcare in the future to ensure that children and adolescents receive the best possible treatment outcomes.

The expected revenue of OrthoPediatrics is 265.24 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of OrthoPediatrics is -29.59 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of OrthoPediatrics is currently -19.57. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the OrthoPediatrics stock.

The price-to-sales ratio (P/S) of OrthoPediatrics is currently 2.18. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the OrthoPediatrics stock.

The Eulerpool Quality Score for OrthoPediatrics is 4/10.

The ISIN of OrthoPediatrics is US68752L1008. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of OrthoPediatrics is A2JAAV. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of OrthoPediatrics is KIDS. The ticker symbol is used to trade OrthoPediatrics shares on the stock exchange.

OrthoPediatrics paid dividends every year for the past 0 years.

OrthoPediatrics is assigned to the 'Health' sector.

The dividends of OrthoPediatrics are distributed in USD.

All fundamentals and in-depth analysis of OrthoPediatrics

Our stock analysis for OrthoPediatrics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OrthoPediatrics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

OrthoPediatrics Stock
OrthoPediatrics Revenue→
OrthoPediatrics Stock
OrthoPediatrics Net Income→
OrthoPediatrics Stock
OrthoPediatrics P/E→
OrthoPediatrics Stock
OrthoPediatrics P/S→
OrthoPediatrics Stock
OrthoPediatrics EBIT→
OrthoPediatrics Stock
OrthoPediatrics Dividend→
OrthoPediatrics Stock
OrthoPediatrics Directors Dealings→
OrthoPediatrics Stock
OrthoPediatrics Stocks→
OrthoPediatrics Stock
OrthoPediatrics Market capitalization→
OrthoPediatrics Stock
OrthoPediatrics Debt→
OrthoPediatrics Stock
OrthoPediatrics Liabilities→
OrthoPediatrics Stock
OrthoPediatrics Equity→
OrthoPediatrics Stock
OrthoPediatrics AAQS→
OrthoPediatrics Stock
OrthoPediatrics Employees→
OrthoPediatrics Stock
OrthoPediatrics ROE→
OrthoPediatrics Stock
OrthoPediatrics ROA→
OrthoPediatrics Stock
OrthoPediatrics ROCE→
OrthoPediatrics Stock
OrthoPediatrics News→
OrthoPediatrics Stock
OrthoPediatrics Analyst Price Targets→

Health Stocks

Ortin GlobalOrthometrixOrtivusOrthofix MedicalOruka TherapeuticsOrthocellOryzon GenomicsOrion OyjOS TherapiesOriola OyjOscotecOrient Pharma CoAll Stocks A–Z →